A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase I Trial in Healthy Male Current Smoker Subjects to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response and Safety of 4 Weeks Oral Administration of BI 1026706

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase I Trial in Healthy Male Current Smoker Subjects to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response and Safety of 4 Weeks Oral Administration of BI 1026706

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs BI 1026706 (Primary)
  • Indications Chronic obstructive pulmonary disease; Osteoarthritis; Postoperative pain
  • Focus Pharmacodynamics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 10 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 09 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Feb 2017.
    • 09 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top